Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-EU expects to get more than a billion COVID-19 shots by September

Tue, 25th May 2021 10:23

* EU to easily meet vaccination targets, 1.5 bln doses by
year-end

* Doses coming from four drugmakers, not Sanofi, CureVac
-document

* EU leaders back goal of donating at least 100 mln doses in
2021

* WHO's Tedros asks for much more
(Adds von der Leyen quotes)

By Sabine Siebold and Francesco Guarascio

BRUSSELS, May 25 (Reuters) - The European Union expects to
have received more than a billion doses of COVID-19 vaccines by
the end of September from four drugmakers, according to a
document presented to EU leaders on Tuesday.

The document, seen by Reuters and prepared by the European
Commission, shows the EU is confident of having enough vaccines
to immunise its entire eligible population by that date, well
beyond the initial goal of inoculating 70% of the adult
population by the end of the summer.

"We are on track to reach our goal," the head of the
European Commission, Ursula von der Leyen, told a news
conference after the meeting with EU leaders. "If we continue
like this, we have confidence that we will be able to safely
reopen our societies."

The EU expects to get 413 million doses in the second
quarter, and another 529 million in the third, according to the
EU document. It received 106 million in the first quarter.

By the end of the year, the EU forecasts it will receive
another 452 million doses, for a total of 1.5 billion.

The estimates take into account only vaccines from
Pfizer/BionTech , Johnson & Johnson,
AstraZeneca and Moderna.

They exclude doses from German biotech CureVac and
French drugmaker Sanofi, which have signed contracts
with the EU for hundreds of millions of doses but are struggling
to develop their vaccines and get them approved by EU
regulators.

The numbers are in line with public commitments and previous
announcements, but also include previously unknown targets for
the second half of the year.

The EU has also said it plans to share at least 100 million
doses this year with poorer nations outside the bloc
.

EU leaders meeting on Tuesday confirmed that commitment in a
joint document, but did not make it more ambitious. Some
vaccines could also be used for a third booster shot or against
variants.

World Health Organization (WHO) director-general Tedros
Adhanom Ghebreyesus thanked the EU for its commitment, but
added: "We need hundreds of millions more doses."

He has also urged rich nations to reconsider plans to
vaccinate teenagers because those vaccines would be more useful
in poorer nations.

Despite Tedros' call, von der Leyen said on Tuesday she
hoped the Pfizer/BioNTech vaccine could be quickly approved by
the EU drugs regulator for teenagers between 12 and 15, noting
that a decision was expected towards the end of the month.

The COVAX programme for distributing vaccines around the
world, backed by the WHO and the Global Alliance for Vaccines
and Immunization (GAVI), has so far shipped only about 70
million vaccine doses of the 2 billion planned for this year, as
wealthy nations have reserved most of those available.

LION'S SHARE

Pfizer and BioNTech's vaccine accounts for more than half
the supplies in the second quarter of this year and for nearly
40% of total deliveries in the third quarter.

The document shows that the two companies will deliver 200
million doses in the July-September period, nearly completing
their contracted commitment to supply 600 million.

The two drugmakers are expected to deliver roughly 200
million doses more in the fourth quarter, the bulk of which
would come from a third contract for up to 1.8 billion doses
signed in May, which runs until 2023.

A Pfizer spokesman declined to comment on the numbers cited
in the EU document.

Deliveries in the second half of the year also include
several million from AstraZeneca, even though it had been
required to deliver all its 300 million contracted doses by the
end of June.

The company said in March it could hope to deliver only 100
million doses to the EU by the end of June due to production
problems and export restrictions.

The EU document is based on the company's estimates rather
than on the EU request to deliver 120 million doses by the end
of the second quarter.

That request was made by EU lawyers in a Brussels court this
month. A ruling is expected next month.
(Reporting by Sabine Siebold and Francesco Guarascio
@fraguarascio in Brussels; additional reporting by Stephanie
Ulmer-Nebehay in Geneva; Editing by John Chalmers, Barbara Lewis
and Nick Macfie)

More News
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.